193

References:

1. Overington JP, Al-Lazikani B, Hopkins AL. "How many drug targets

are there?" Nat Rev Drug Discov 5 (12), 2006, 993.

2. Filmore, David. "It's a GPCR world". Modern Drug Discovery. 2004,

24.

3. Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane

EJ, Saxena PR, Humphrey. "International Union of Pharmacology

classification of receptors for 5-hydroxytryptamine (Serotonin)".

Pharmacol. Rev. 46 (2), 1994, 157.

4. Frazer A, Hensler JG. "Chapter 13: Serotonin Receptors". In Siegel

GJ, Agranoff BW, Albers RW, Fisher SK, Uhler MD. "Basic

Neurochemistry: Molecular, Cellular, and Medical Aspects”.

Philadelphia: Lippincott-Raven. 1999, 263.

5. Nichols DE, Nichols CD. "Serotonin receptors". Chem. Rev. 108 (5),

2008, 1614.

6. Nagel B, Dellweg H, Gierasch LM. “Glossary for Chemists of the

terms used in biotechnology” Pure Appl. Chem. Vol. 64 (1), 1992,

143.

7. Schneider P, Tanrikulu Y, Schneider G. “Self-organizing maps in

drug discovery: compound library design, scaffold-hopping,

repurposing.” Curr Med Chem. 16 (3), 2009, 258.

194

8. Milligan G. "Constitutive activity and inverse agonists of G protein-

coupled receptors: a current perspective". Mol. Pharmacol. 64 (6),

2003, 1271.

9. Baaske P, Wienken CJ, Reineck P, Duhr S, Braun D. "Optical

Thermophoresis quantifies Buffer dependence of Aptamer Binding".

Angew. Chem. Int. Ed. 49 (12), 2010, 1.

10. Connolly CN, Wafford KA. "The Cys-loop superfamily of ligand-gated

ion channels: the impact of receptor structure on function". Biochem.

Soc. Trans. 32 (Pt3), 2004, 529.

11. Dudek RW. High-yield cell and molecular biology, Lippincott williams

& wilkins. 2006, 19.

12. Geuze HJ, Jan W. Slot JW, Peppard J, Figura KV, Hasilik A,

Schwartz AL “Intracellular receptor sorting during endocytosis:

Comparative immunoelectron microscopy of multiple receptors in rat

liver” Cell, 37 (1), 1984, 195.

13. Goodman and Gilman's Manual of Pharmacology and Therapeutics.

2008, 14.

14. Negus SS, "Some implications of receptor theory for in vivo

assessment of agonists, antagonists and inverse agonists". Biochem.

Pharmacol. 71 (12), 2006, 1663.

15. Gobeil F, “G-protein-coupled receptors signalling at the cell nucleus:

an emerging paradigm”. Can J Physiol Pharmacol. 84 (3 - 4), 2006,

287.

195

16. King N, Hittinger CT, Carroll SB. "Evolution of key cell signaling and

adhesion protein families predates animal origins". Science 301

(5631), 2003, 361.

17. Gilman AG. "G Proteins: Transducers of Receptor Generated

Signals". Annual Review of Biochemistry 56, 1987, 615.

18. Wettschureck N, Offermanns S. "Mammalian G proteins and their

cell type specific functions". Physiol. Rev., 85 (4), 2005, 1159.

19. Hallows KR, Alzamora R. "AMP-activated protein kinase inhibits

alkaline pH- and PKA-induced apical vacuolar H+-ATPase

accumulation in epididymal clear cells". Am. J. Physiol., Cell Physiol.

296 (4), 2009, C672.

20. Mellor H, Parker PJ. "The extended protein kinase C superfamily".

Biochem. J. 332 (Pt 2), 1998, 281.

21. Glennon RA, Dukat M, Westkaemper. "Serotonin Receptor Subtypes

and Ligands". American College of Neurophyscopharmacology. 2008.

22. Pazos A, Palacios JM. “Quantitative Autoradiographic Mapping of

Serotonin Receptors in the Rat Brain. I. Serotonin-1 Receptors”.

Brain Res. 346, 1985, 205.

23. Larsson LG, Rényi L, Ross SB, Svensson B, Angeby-Möller K.

"Different effects on the responses of functional pre- and

postsynaptic 5-HT1A receptors by repeated treatment of rats with the

5-HT1A receptor agonist 8-OH-DPAT". Neuropharmacology. 29 (2),

1990, 85.

196

24. Fornal CA, Metzler CW, Gallegos RA, Veasey SC, McCreary AC,

Jacobs BL. "WAY-100635, a potent and selective 5-

hydroxytryptamine1A antagonist, increases serotonergic neuronal

activity in behaving cats: comparison with (S)-WAY-100135". The

Journal of Pharmacology and Experimental Therapeutics. 278 (2),

1996, 752.

25. Yadav VK, Ryu JH, Suda N, Tanaka KF, Gingrich JA, Schütz G,

Glorieux FH, Chiang CY, Zajac JD, Insogna KL, Mann JJ, Hen R,

Ducy P, Karsenty G. "Lrp5 controls bone formation by inhibiting

serotonin synthesis in the duodenum". Cell 135 (5), 2008, 825.

26. Koe KB, Nielsen JA, Macor JE, Heym J. “Biochemical and behavioral

studies of the 5-HT1B receptor agonist, CP-94,253”. Drug

Development Research. 26 (3), 1992, 241.

27. Hudzik TJ, Yanek M, Porrey T, Evenden J, Paronis C, Mastrangelo M,

Ryan C, Ross S, Stenfors C. “Behavioral pharmacology of AR-

A000002, a novel, selective 5-hydroxytryptamine(1B) antagonist”.

Journal of Pharmacology and Experimental Therapeutics. 304 (3),

2003, 1072.

28. Glennon RA, Hong SS, Dukat M, Teitler M, Davis K. "5-(Nonyloxy)

tryptamine: a novel high-affinity 5-HT1D beta serotonin receptor

agonist". J. Med. Chem. 37 (18), 1994, 2828.

29. Easthope SE, Goa KL. Frovatriptan. CNS Drugs.15 (12), 2001, 969.

197

30. Schlicker E, Fink K, Molderings GJ, Price GW, Duckworth M, Gaster

L, Middlemiss DN, Zentner J, Likungu J, Göthert M. “Effects of

selective h5-HT1B (SB-216641) and h5-HT1D (BRL-15572) receptor

ligands on guinea-pig and human 5-HT auto- and heteroreceptors”.

Naunyn Schmiedebergs Archives of Pharmacology. 356 (3), 1997,

321.

31. Bai F, Yin T, Johnstone EM, Su C, Varga G, Little SP, Nelson DL.

"Molecular cloning and pharmacological characterization of the

guinea pig 5-HT1E receptor." European journal of pharmacology. 484

(2-3), 2004, 127.

32. John E. Macor & Martin J. Wythes, “Indole Derivatives” U.S. Patent

no. 5545644, August 13, 1996.

33. Monachon MA, Burkard WP, Jalfre M, Haefely W. "Blockade of

central 5-hydroxytryptamine receptors by methiothepin". Naunyn

Schmiedebergs Arch. Pharmacol. 274 (2), 1972, 192.

34. Adham N, Kao HT, Schecter LE, Bard J, Olsen M, Urquhart D,

Durkin M, Hartig PR, Weinshank RL, Branchek TA. "Cloning of

another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor

subtype coupled to the inhibition of adenylate cyclase". Proc. Natl.

Acad. Sci. U.S.A. 90 (2), 1993, 408.

35. Wainscott DB, Krushinski JH, Audia JE, Schaus JM, Zgombick JM,

Lucaites VL, Nelson DL. "[3H]-LY-334,370, a novel radioligand for the

198

5-HT1F receptor. In vitro characterization of binding properties".

Naunyn Schmiedebergs Arch. Pharmacol. 371 (3), 2005, 169.

36. Eison AS, Mullins UL. "Regulation of central 5-HT2A receptors: a

review of in vivo studies". Behavioural Brain Research. 73 (1–2),

1996, 177.

37. Cook EH, Fletcher KE, Wainwright M, Marks N, Yan SY, Leventhal

BL. "Primary structure of the human platelet serotonin 5-HT2

receptor: identity with frontal cortex serotonin 5-HT2A receptor". J.

Neurochem. 63 (2), 1994, 465.

38. Passie T, Halpern JH, Stichtenoth DO, Emrich HM, Hintzen A. "The

Pharmacology of Lysergic Acid Diethylamide: a Review". CNS

Neuroscience & Therapeutics. 14 (4), 2008, 295.

39. Akhondzadeh S, Malek-Hosseini M, Ghoreishi A, Raznahan M,

Rezazadeh SA. "Effect of ritanserin, a 5HT2A/2C antagonist, on

negative symptoms of schizophrenia: A double-blind randomized

placebo-controlled study". Progress in neuro-psychopharmacology &

biological psychiatry. 32 (8), 2008, 1879.

40. Callebert J, Esteve JM, Hervé P, Peoc'h K, Tournois C, Drouet L,

Launay JM, Maroteaux L. "Evidence for a control of plasma serotonin

levels by 5-hydroxytryptamine (2B) receptors in mice". J. Pharmacol.

Exp. Ther. 317 (2), 2006, 724.

199

41. Kennett GA, Bright F, Trail B, Baxter GS, Blackburn TP. "Effects of

the 5-HT2B receptor agonist, BW 723C86, on three rat models of

anxiety". British journal of pharmacology. 117 (7), 1996, 1443.

42. Bonhaus DW, Flippin LA, Greenhouse RJ, Jaime S, Rocha C,

Dawson M, Van Natta K, Chang LK, Pulido-Rios T, Webber A, Leung

E, Eglen RM, Martin GR. “RS-127445: a selective, high affinity, orally

bioavailable 5-HT2B receptor antagonist”. British Journal of

Pharmacology. 127 (5), 1999, 1075.

43. Alex KD, Yavanian GJ, McFarlane HG, Pluto CP, Pehek EA.

"Modulation of dopamine release by striatal 5-HT2C receptors".

Synapse. 55 (4), 2005, 242.

44. Heisler LK, Zhou L, Bajwa P, Hsu J, Tecott LH (July). "Serotonin 5-

HT2C receptors regulate anxiety-like behavior". Genes, Brain and

Behavior. 6 (5), 2007, 491.

45. Fletcher PJ, Rizos Z, Sinyard J, Tampakeras M, Higgins GA. “The 5-

HT2C receptor agonist Ro60-0175 reduces cocaine self-administration

and reinstatement induced by the stressor yohimbine, and

contextual cues”. Neuropsychopharmacology. 33 (6), 2008, 1402.

46. Kennett GA, Wood MD, Bright F, Trail B, Riley G, Holland V, Avenell

KY, Stean T. "SB 242084, a selective and brain penetrant 5-HT2C

receptor antagonist". Neuropharmacology. 36 (4-5), 1997, 609.

47. Yakel JL, Endo M, Kurachi Y, Mishina M. “The 5-HT3 receptor

channel: function, activation and regulation in Pharmacology of Ionic

200

Channel Function: Activators and Inhibitors (Handbook of

Experimental Pharmacology)”. 147, Berlin: Springer-Verlag, 2000,

541.

48. Dukat M, Young R, Darmani NN, Ahmed B, Glennon RA. "The 5-HT3

agent N-(3-chlorophenyl) guanidine (MD-354) serves as a

discriminative stimulus in rats and displays partial agonist character

in a shrew emesis assay". Psychopharmacology. 150 (2), 2000, 200.

49. PRNewswire. FDA Approves Granistron (Sancuso), the First and Only

Patch for Preventing Nausea and Vomiting in Cancer Patients

Undergoing Chemotherapy. September 12, 2008.

50. Hegde SS, Eglen RM. "Peripheral 5-HT4 receptors". The FASEB

journal. 10 (12), 1996, 1398.

51. Lucas G, Rymar VV, Du J, Mnie-Filali O, Bisgaard C, Manta S,

Lambas-Senas L, Wiborg O, Haddjeri N, Piñeyro G, Sadikot AF,

Debonnel G. "Serotonin (4) (5-HT (4)) Receptor Agonists Are Putative

Antidepressants with a Rapid Onset of Action.” Neuron. 55 (5), 2007,

712.

52. Birkeland JA. “Effects of treatment with a 5-HT4 receptor antagonist

in heart failure”. Br J Pharmacol. 150 (2), 2007, 143.

53. Francken BJ, Jurzak M, Vanhauwe JF, Luyten WH, Leysen JE. "The

human 5-ht5A receptor couples to Gi/Go proteins and inhibits

adenylate cyclase in HEK 293 cells". Eur. J. Pharmacol. 361 (2-3),

1998, 299.

201

54. Thomas DR, Soffin EM, Roberts C, Kew JN, Flor RM, Dawson LA, Fry

VA, Coggon SA, Faedo S, Hayes PD, Corbett DF, Davies CH, Hagan

JJ. “SB-699551-A (3-cyclopentyl-N-[2-(dimethylamino) ethyl]-N-[(4'-

{[(2-phenylethyl) amino] methyl}-4-biphenylyl) methyl] propanamide

dihydrochloride), a novel 5-ht5A receptor-selective antagonist,

enhances 5-HT neuronal function: Evidence for an autoreceptor role

for the 5-ht5A receptor in guinea pig brain”. Neuropharmacology.

51(3), 2006, 566.

55. Woolley ML, Marsden CA, Fone KC. "5-HT6 receptors". Current Drug

Targets. CNS and Neurological Disorders. 3 (1), 2004, 59.

56. Gérard C, Martres MP, Lefèvre K. "Immuno-localization of serotonin

5-HT6 receptor-like material in the rat central nervous system". Brain

Research. 746 (1-2), 1997, 207.

57. Hamon M, Doucet E, Lefèvre K. "Antibodies and antisense

oligonucleotide for probing the distribution and putative functions of

central 5-HT6 receptors".Neuropsychopharmacology. 21 (2), 1999,

68S.

58. Dawson LA, Nguyen HQ. "In vivo effects of the 5-HT (6) antagonist

SB-271046 on striatal and frontal cortex extracellular concentrations

of noradrenaline, dopamine, 5-HT, glutamate and aspartate". British

Journal of Pharmacology. 130 (1), 2000, 23.

59. Dawson LA, Nguyen HQ. "The 5-HT (6) receptor antagonist SB-

271046 selectively enhances excitatory neurotransmission in the rat

202

frontal cortex and hippocampus". Neuropsychopharmacology. 25 (5),

2001, 662.

60. King MV, Sleight AJ, Woolley ML, Topham IA, Marsden CA, Fone KC.

"5-HT6 receptor antagonists reverse delay-dependent deficits in novel

object discrimination by enhancing consolidation an effect sensitive

to NMDA receptor antagonism". Neuropharmacology. 47 (2), 2004,

195.

61. Orlacchio A, Kawarai T, Paciotti E. "Association study of the 5-

hydroxytryptamine (6) receptor gene in Alzheimer's disease."

Neurosci. Lett. 325 (1), 2002, 13.

62. Schechter LE, Lin Q, Smith DL. "Neuropharmacological profile of

novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-

208466". Neuropsychopharmacology. 33 (6), 2008, 1323.

63. Lacroix LP, Dawson LA, Hagan JJ, Heidbreder CA. "5-HT6 receptor

antagonist SB-271046 enhances extracellular levels of monoamines

in the rat medial prefrontal cortex". Synapse. 51 (2), 2004,158.

64. King MV, Marsden CA, Fone KC. "A role for the 5-HT (1A), 5-HT4 and

5-HT6 receptors in learning and memory". Trends in Pharmacological

Sciences. 29 (9), 2008, 482.

65. Arnt J, Bang-Andersen B, Grayson B, Bymaster FP, Cohen MP,

DeLapp NW, Giethlen B, Kreilgaard M, McKinzie DL, Neill JC, Nelson

DL, Nielsen SM, Poulsen MN, Schaus JM, Witten LM. “Lu AE58054,

a 5-HT (6) antagonist, reverses cognitive impairment induced by

203

subchronic phencyclidine in a novel object recognition test in rats”.

Int J Neuropsychopharmacol. 13(8), 2010, 1021.

66. Maher-Edwards G, Zvartau-Hind M, Hunter AJ. "Double-Blind,

Controlled Phase II Study of a 5-HT6 Receptor Antagonist, SB-

742457, in Alzheimer's Disease". Current Alzheimer Research. 7 (5),

2010, 374.

67. Nicola C, Sandrine A, Mark J, Michael W, Jesse C, Bruno V.

“Suitability of the Clinical Dementia Rating-Sum of Boxes as a single

primary endpoint for Alzheimer’s disease trials”. Alzheimer’s

Dementia 7 (6), 2011, 593.

68. Shacham S, Heal DJ, Cheetham SC, Jackson HC, Melendez R,

Rutkowski JV, Orbach P & Gannon KS. “PRX-07034, a Potent and

Selective 5-HT6 Receptor Antagonist, Reduces Food Intake and Body

Weight in Rats" Society for Neuroscience, Washington, DC, 2006.

69. Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. "Selective 5-

HT6 receptor ligands: progress in the development of a novel

pharmacological approach to the treatment of obesity and related

metabolic disorders". Pharmacol Ther. 117 (2), 2008, 207.

70. Frassetto A, Zhang J, Lao JZ. "Reduced sensitivity to diet-induced

obesity in mice carrying a mutant 5-HT6 receptor". Brain Research.

1236, 2008, 140.

204

71. Schechter LE, Lin Q, Smith DL. "Neuropharmacological profile of

novel and selective 5-HT6 receptor agonists: WAY-181187 and WAY-

208466". Neuropsychopharmacology. 33 (6), 2008, 1323.

72. Mattsson C, Sonesson C, Sandahl A, Greiner HE, Gassen M,

Plaschke J, Leibrock J, Böttcher H. "2-Alkyl-3-(1, 2, 3, 6-

tetrahydropyridin-4-yl)-1H-indoles as novel 5-HT6 receptor agonists".

Bioorg. Med. Chem. Lett. 15 (19), 2005, 4230.

73. Abate C, Kolanos R, Dukat M, Setola V, Roth BL, Glennon RA.

"Interaction of chiral MS-245 analogs at h5-HT6 receptors".

Bioorganic & medicinal chemistry letters. 15 (15), 2005, 3510.

74. Jasti V, Ramakrishna VSN, Kambhampati RS, Shirsath VS,

Vishwottam NK. “Preparation of pyrrolidinyl indoles as 5HT6 receptor

modulators” PCT Int.Appl. WO 2005066157; Chem.Abstr.143:

153282, 2005.

75. Cole DC, Ellingboe JW, Mazandarani H, Smith DL, Stock JR, Zhon P,

Schechter LE. “N1-Arylsulfonyl-3-(1,2,3,6-tetrahydropyridin-4-yl)-1H-

indole derivatives are potent and selective 5-HT6 receptor

antagonists”. Bioorg. Med. Chem. Lett. 15, 2005, 379.

76. Ramakrishna VSN, Shirasath VS, Kambhampati RS, Despande AD,

Daultabad AV, Vishwakarma S, Jasti V. “3-(Heterocyclyl)-N-

(arylsulfonyl) indole derivatives as functional 5-HT6 ligands” PCT Int.

Appl., WO 2007138611; Chem.Abstr. 148:33622, 2007.

205

77. Ramakrishna NVS, Kambhampati RS, Despande AD. Jasti V. “4-

(Heterocyclyl) alkyl-N-(arylsulfonyl) indole compounds and their use

of 5-HT6 ligands” PCT Int. Appl., WO 2008084491; Chem Abstr.

149:176374, 2009.

78. Ramakrishna NVS, Kambhampati RS, Shirasath VS, Jasti V. “N-

Arylsulfonyl-3-substituted indoles having serotonin receptor affinity,

process for their preparation and pharmaceutical composition

containing them” International Patent application WO 2004/048330,

2004.

79. Ruat M, Traiffort E, Leurs R, Tardivel-Lacombe J, Diaz J, Arrang JM,

Schwartz JC. "Molecular cloning, characterization, and localization of

a high-affinity serotonin receptor (5-HT7) activating cAMP formation".

Proc. Natl. Acad. Sci. U.S.A. 90 (18), 1993, 8547.

80. Meneses A, Perez-Garcia G, Liy-Salmeron G, Flores-Galvez D,

Castillo C, Castillo E. "The effects of the 5-HT (6) receptor agonist

EMD and the 5-HT (7) receptor agonist AS19 on memory formation".

Behavioural brain research. 195 (1), 2008, 112.

81. Abbas AI, Hedlund PB, Huang XP, Tran TB., Meltzer HY, Roth BL.

"Amisulpride is a potent 5-HT7 antagonist: relevance for

antidepressant actions in vivo". Psychopharmacology (Berl.). 205 (1),

2009, 119.

82. Davies SL, Silvestre JS, Guitart X. “Drug discovery targets”.

Drugs Future. 30, 2005, 479.

206

83. Slassi A, Isaac M, O'Brien A. “Recent progress in 5-HT6 receptor

antagonists for the treatment of CNS diseases”. Expert Opin. Ther.

Pat. 12, 2002, 513.

84. Monsma FJ, Shen Y, Ward RP, Hamblin MW, Sibley DR. “Cloning

and expression of a novel serotonin receptor with high affinity for

tricyclic psychotropic drugs”. Mol. Pharmacol. 43, 1993, 320.

85. Boess, FG, Riemer C, Bos M, Bentley J, Bourson A,Sleight AJ. “The

5-hydroxytryptamine-6 receptor-selective radioligand [3H] Ro 63-

0563 labels 5-hydroxytryptamine receptor binding sites in rat and

porcine striatum”. Mol. Pharmacol. 54, 1998, 577.

86. Kohen R, Metcalf MA, Khan N, Druck T, Huebner K, Lachowicz JE,

Meltzer HY, Sibley DR, Roth BL, Hamblin MW. “Cloning,

characterization, and chromosomal localization of a human 5-HT6

serotonin receptor”. J. Neurochem. 66, 1996, 47.

87. Roth BL, Craigo SC, Choudhary MS, Uluer A, Monsma FJ , Shen Y,

Meltzer HY, Sibley DR. “Binding of typical and atypical antipsychotic

agents to 5-hydroxytryptamine-6 and 5- hydroxytryptamine-7

receptors”. J. Pharmacol. Exp. Ther. 268, 1994, 1403.

88. Glatt CE, Snowman AM, Sibley DR, Snyder SH. “Clozapine: selective

labeling of sites resembling 5-HT6 serotonin receptors may reflect

psychoactive profile”. Mol. Med, 1, 1995, 398.

89. Bourson A, Borroni E, Austin RH, Monsma FJ, Sleight AJ.

“Determination of the role of the 5-HT6 receptor in the rat brain: a

207

study using antisense oligonucleotides”. J. Pharmacol. Exp. Ther.

274, 1995, 173.

90. Yoshioka M, Matsumoto M, Togashi H, Mori K. “Central distribution

and function of 5-HT6 receptor subtype in the rat brain”. Ann. N. Y.

Acad Sci. 861, 1998, 244.

91. Woolley ML, Bentley JC, Sleight AJ, Marsden CA, Fone KC. “A role

for 5-HT6 receptors in retention of spatial learning in the Morris

water maze”. Neuropharmacology. 41, 2001, 210.

92. Bentley JC, Bourson A, Boess FG, Fone KC, Marsden CA, Petit N,

Sleight AJ. “Investigation of stretching behaviour induced by the

selective 5-HT6 receptor antagonist, Ro 04-6790, in rats”. Br. J.

Pharmacol. 126, 1999, 1537.

93. Sleight AJ, Boess FG, Bos M, Levet-Trafit B, Riemer C, Bourson A.

“Characterization of Ro 04-6790 and Ro 63-0563: potent and

selective antagonists at human and rat 5-HT6 receptors”. Br. J.

Pharmacol. 124, 1998, 556.

94. Bromidge SM, Brown AM, Clarke SE, Dodgson K, Gager T, Grassam

HL, Jeffrey PM, Joiner GF, King FD, Middlemiss DN, Moss SF,

Newman H, Riley G, Routledge C, Wyman P. “5- Chloro-N-(4-

methoxy-3-piperazin-1- yl- phenyl)-3-methyl-2-

benzothiophenesulfon- amide (SB-271046): a potent, selective, and

orally bioavailable 5-HT6 receptor antagonist”. J. Med. Chem. 42,

1999, 202.

208

95. Routledge C, Bromidge SM, Moss SF, Price GW, Hirst W, Newman H,

Riley G, Gager T, Stean T, Upton N, Clarke SE, Brown AM,

Middlemiss DN. “Characterization of SB-271046: a potent, selective

and orally active 5-HT6 receptor antagonist”. Br. J. Pharmacol. 130,

2000, 1606.

96. Hirst WD, Stean TO, Rogers DC, Sunter D, Pugh P, Moss SF,

Bromidge SM, Riley G, Smith DR, Bartlett S, Heidbreder CA,

Atkins AR, Lacroix LP, Dawson LA, Foley AG, Regan CM, Upton N.

“SB-399885 is a potent, selective 5-HT6 receptor antagonist with

cognitive enhancing properties in aged rat water maze and novel

object recognition models”. Eur. J. Pharmacol. 553, 2006, 109.

97. Schreiber R, Vivian J, Hedley L, Szczepanski K, Secchi R L, Zuzow

M, van Laarhoven S, Moreau J L, Martin J R, Sik A, Blokland A.

“Effects of the novel 5-HT6 receptor antagonist Ro 4368554 in rat

models for cognition and sensorimotor gating”. Eur.

Neuropsychopharmacol. 17, 2007, 277.

98. Upton N, Chuang TT, Hunter AJ, Virley DJ. "5-HT6 receptor

antagonists as novel cognitive enhancing agents for Alzheimer's

disease". NeuroTherapeutics. 5 (3), 2008, 458.

99. Kuperberg G, Heckers S. “Schizophrenia and cognitive function”.

Curr. Opin. Neurobiol. 10, 2000, 205.

100. Lee KH, Brown WH, Egleston PN, Green RD, Farrow TF, Hunter MD,

Parks RW, Wilkinson D, Spence SA, Woodruff PW. “A functional

209

magnetic resonance imaging study of social cognition in

schizophrenia during an acute episode and after recovery”. Am. J.

Psychiatry. 163, 2006, 1926.

101. Loiseau F, Dekeyne A, Millan MJ. “Pro-cognitive effects of 5- HT6

receptor antagonists in the social recognition procedure in rats:

implication of the frontal cortex”. Psychopharmacology. 196, 2008,

93.

102. Mitchell ES, Hoplight BJ, Lear SP, Neumaier JF. “BGC20-761, a

novel tryptamine analog, enhances memory consolidation and

reverses scopolamine-induced memory deficit in social and

visuospatial memory tasks through a 5-HT6 receptormediated

mechanism”. Neuropharmacology. 50, 2006, 412.

103. Schaffhauser H, Mathiasen JR, DiCamillo A, Huffman MJ, Lu LD,

McKenna BA, Qian J, Marino MJ. “Dimebolin is a 5-HT6 antagonist

with acute cognition enhancing activities”. Biochem. Pharmacol. 78

(8), 2009, 1035.

104. Dawson LA, Nguyen HQ. “In vivo effects of the 5-HT (6) antagonist

SB-271046 on striatal and frontal cortex extracellular concentrations

of noradrenaline, dopamine, 5-HT, glutamate and aspartate”. Br. J.

Pharmacol. 130, 2000, 23.

105. Dawson LA, Nguyen HQ. “The 5-HT(6) receptor antagonist SB-

271046 selectively enhances excitatory neurotransmission in the rat

210

frontal cortex and hippocampus”. Neuropsychopharmacology. 25,

2001, 662.

106. Lacroix LP, Dawson LA, Hagan JJ, Heidbreder CA. “5- HT6 receptor

antagonist SB-271046 enhances extracellular levels of monoamines

in the rat medial prefrontal cortex”. Synapse. 51, 2004, 158.

107. Schechter LE, Lin Q, Smith DL, Zhang G, Shan Q, Platt B, Brandt M

R, Dawson LA, Cole D, Bernotas R, Robichaud A, Rosenzweig-Lipson

S, Beyer CE. “Neuropharmacological Profile of Novel and Selective 5-

HT (6) Receptor Agonists: WAY-181187 and WAY-208466”.

Neuropsychopharmacology. 33 (6), 2008, 1323.

108. Heal DJ, Smith SL, Fisas A, Codony X, Buschmann H. “Selective 5-

HT6 receptor ligands: progress in the development of a novel

pharmacological approach to the treatment of obesity and related

metabolic disorders”. Pharmacol. Ther. 117, 2008, 207.

109. Glennon RA, Bondarev M, Roth BL. “5-HT6 serotonin receptor

binding of indolealkylamines: a preliminary structure-affinity

investigation”. Med. Chem. Res. 9, 1999, 108.

110. Glennon RA, Lee M, Rangisetty JB, Dukat M, Roth BL, Savage JE,

McBride A, Rauser L, Hufeisen S, Lee DKH. “2-Substituted

Tryptamines: Agents with Selectivity for 5-HT6 Serotonin Receptors”.

J. Med. Chem. 43, 2000, 1011.

111. Tsai Y, Dukat M, Slassi A, MacLean N, Demchyshyn L, Savage JE,

Roth BL, Hufesein S, Lee M, Glennon RA. “N1-(

211

Benzenesulfonyl)tryptamines as novel 5-HT6 antagonists”. Bioorg.

Med. Chem. Lett. 10, 2000, 2295.

112. Russell MGN, Baker RJ, Barden L, Beer MS, Bristow L, Broughton H

B, Knowles M, McAllister G, Patel S, Castro JL. “N-

Arylsulfonylindole derivatives as serotonin 5-HT6 receptor ligands”. J.

Med. Chem. 44, 2001, 3881.

113. Cole DC, Stock JR, Lennox WJ, Bernotas RC, Ellingboe JW, Boikess

S, Coupet J, Smith DL, Leung L, Zhang GM, Feng X, Kelly MF,

Galante R, Huang P, Dawson LA, Marquis K, Rosenzweig-Lipson S,

Beyer CE, Schechter LE. “Discovery of N1-(6-chloroimidazo[2,1-

b][1,3]thiazole-5-sulfonyl) tryptamine as a potent, selective, and

orally active 5-HT(6) receptor agonist”. J. Med. Chem. 50, 2007,

5535.

114. Cole DC, Stock JR, Lennox WJ, Bernotas RC, Ellingboe JW, Leung L,

Smith D, Zhang G, Qian L, Dawson LA, Boikess S, Rosenzweig-

Lipson S, Beyer CE, Schechter LE. “Discovery of a potent, selective

and orally active 5-HT6 receptor agonist, WAY-181187”. Abstracts of

Papers, 230th ACS National Meeting, Washington, DC, United States,

Aug. 28-Sept. 1, 2005, MEDI-017.

115. Cole DC, Stock JR, Lennox WJ, Zhou P. “Preparation of

indolylalkylamines as 5-hydroxytryptamine-6 ligands”. WO A1

2003053433, 2003.

212

116. Holenz J, Pauwels PJ, Diaz JL, Merce R, Codony X, Buschmann H.

“Medicinal chemistry strategies to 5-HT6 receptor ligands as potential

cognitive enhancers and antiobesity agents”.Drug Discov. Today, 11,

2006, 283.

117. Liu KG, Robichaud AJ. “5-HT6 antagonists as potential treatment for

cognitive dysfunction”. Drug Dev. Res. 70, 2009, 145.

118. Fu JM. “Preparation of arylsulphonyl-substituted tetrahydro- and

hexahydrocarbazolamines as 5-HT6 receptor ligands”. WO A1

2003030901, 2003.

119. Fu JM. “Preparation of 5-(arylsulfonyl) indoles having 5-HT6 receptor

affinity for treatment of CNS disorders”. WO A1 2003011284, 2003.

120. Zhou P, Yan Y, Bernotas R, Harrison BL, Huryn D, Robichaud AJ,

Zhang GM, Smith DL, Schechter LE. “4- (2-Aminoethoxy)-N-

(phenylsulfonyl)indoles as novel 5-HT6 receptor ligands”. Bioorg. Med.

Chem. Lett. 15, 2005, 1393.

121. Kelly MG, Cole DC. “Preparation of 1-aryl- or 1-

alkylsulfonylheterocyclylbenzazoles as 5-hydroxytryptamine-6

ligands”. WO A2 2002036562, 2002.

122. Beard CC, Clark RD, Fisher LE, Harris RN, Repke DB. “Preparation

of new indole derivatives with 5-HT6 receptor affinity”. WO A1

2002098857, 2002.

123. Madera AM, Weikert RJ. “Preparation of 2,7-substituted indoles as 5-

HT6 modulators”. WO A1 2004026830, 2004.

213

124. Madera AM, Weikert RJ. “Preparation of 2,7-substituted indoles as 5-

HT6 modulators”. WO A1 2004026831, 2004.

125. Holenz J, Merce R, Diaz JL, Guitart X, Codony X, Dordal A, Romero

G, Torrens A, Mas J, Andaluz B, Hernandez S, Monroy X, Sanchez

E, Hernandez E, Perez R, Cubi R, Sanfeliu O, Buschmann H.

“Medicinal chemistry driven approaches toward novel and selective

serotonin 5-HT6 receptor ligands”. J. Med. Chem. 48, 2005, 1781.

126. Filla SA, Flaugh ME, Gillig JR, Heinz LJ, Krushinski JH.

“Preparation of benzenesulfonic acid indol-5-yl esters as antagonists

of the 5-HT6 receptor”. WO A2 2002060871, 2002.

127. Pineiro-Nunez MM, Bauzon DD, Bymaster FP, Chen Z, Chernet E,

Clay MP, Crile R, DeLapp NW, Denny CP, Falcone JF, Flaugh ME,

Heinz LJ, Kiefer AD, Koch DJ, Krushinski JH, Leander JD,

Lindstrom TD, Liu B, McKinzie DL, Nelson DL, Phebus LA, Rocco V

P, Schaus JM, Wolff MC, Ward JS. “Discovery and SAR studies of

2,6-difluorobenzenesulfonic acid 1-methyl-3-(1- methylpiperidin-4-

yl)-1H-indol-5-yl ester, a novel and potent 5- HT6 antagonist for the

treatment of cognitive deficit”. Abstracts of Papers, 229th ACS

National Meeting, San Diego, CA, United States, March 13-17, 2005,

MEDI-282.

128. Lopez-Rodriguez ML, Benhamu B, Sanz A, Pardo L, Campillo M. “A

three-dimensional pharmacophore model for 5-

hydroxytryptamine6 (5-HT6) receptor antagonists”. J. Med. Chem.

214

48, 2005, 4216.

129. Batcho AD, Leimgruber W. “Indoles from 2-methyl nitro benzene by

condensation with formamide acetal followed by reduction”Org.

Synth, 63, 1985, 214.

130. Batcho AD, Leimgruber W. “Process & intermediate for the

preparation of indoles from ortho nitro toulenes” U.S Patent

3,732,245 & U.S. Patent 3,976,639, 1973.

131. Kelly, Micheal, Gerard. “1-Aryl-or 1-alkylsulfonyl-hetrocyclbenzazoles

as 5-HT6 ligands” WO 02/36562 A2, 2002.

132. Beard, Collin Charles, Clark, Robin, Douglas, Fisher Lawrence

Emerson. “‘New indole derivatives with 5-HT6R affinity” WO

02/098857 A1, 2002.

133. Ellen W, Baxter, Allen B, Reitz. “Reductive Aminations of

Carbonyl Compounds with Borohydride and Borane Reducing

Agents” Organic Reactions. 1, 2002, 59.

134. Bromidge, Steven, Mark.”Compound useful in the treatments of CNS

disorder” WO 02/41889 A2, 2002.

135. Nyandege A, Kolanos R, Roth BL, Glennon RA, “Further studies on

the binding of N1-substituted tryptamines at h5-HT6 receptors”.

Bioorganic & Medicinal Chemistry Letters. 17, 2007, 1691.

136. Chang-Fong J, Jagadeesh BR, Dokat M, Setola V, Thomas R,

Roth B, Glennon RA. “1,2,3,4-Tetrahydrocarbazoles as 5-HT6

215

serotonin receptor ligands”. Bioorganic & Medicinal Chemistry Letters.

14 (8), 2004, 1961.

137. Gewald K, Schinke E, Böttcher H.“Gewald’s reaction mechanisim“

Ber. 99, 1966, 94.

138. Ming WD, Jun XU R, Feng CHEN Y. A Selective Synthesis of 2-

Alkylamino-5,6,7,8-tetrahydro-benzothieno[2,3-d]pyrimidin-

4(3H)-ones”. Chinese Chemical Letters. Vol. 16 (2), 2005, 189.

139. Sachin LS, Bhatnagar SP. “Efficient Niementowski synthesis of novel

derivatives of 1,2,9,11-tetrasubstituted-7H-

thieno[2’,3’:4,5]pyrimido[6,1-b]-quinazolin-7-one”. ARKIVOC. (xvii)

2008, 212.

140. Temple DL, Yevich JP, Covington RR, Hanning CA, Seidehmed RJ,

Mackey HK, Bartek MJ. “Synthesis of 3,4-Dihydro-4-oxothieno[2,3-

d]pyrimidine-2-carboxylates, a New Series of Orally Active Antiallergy

Agents”. Journal of Medicinal Chemistry. Vol. 22 (5), 1979, 505.

141. Fatma EM, Hanan A.S, Hassan M. “Synthesis of Some

Thienopyrimidine Derivatives”. Molecules. 11, 2006, 498.

142. Bhujyan MN, Khandker MD, Mizanur RMD, Kammrul HAR, Ismail H

MD, Abu MD. “Synthesis and antimicrobial evalution of some new

thienopyrimidine derivatives”. Acta Pharm. 56, 2006, 441.

143. Vallance P, Smart TG. "The future of pharmacology" British journal of

pharmacology. 147 (1), 2006, S304.

216

144. Balani SK, Miwa GT, Gan LS, Wu JT, Lee FW. "Strategy of utilizing in

vitro and in vivo ADME tools for lead optimization and drug

candidate selection". Curr Top Med Chem. 5 (11), 2005, 1033.

145. http://www.merckmanuals.com/professional/sec21/ch324/ch324d.

html“Volume of distribution (VD)”

146. Semple KT, Doick KJ, Jones KC, Burauel P, Craven A, Harms H.

“Defining bioavailability and bioaccessibility of contaminated soil

and sediment is complicated". Environ. Sci. Technol. 38 (12), 2004,

228A.

147. Tracy TS. "Pharmacokinetics". In Stitzel RE, Craig CF. Modern

pharmacology with clinical applications. Hagerstwon, MD:

Lippincott Williams & Wilkins. 2004, 49.

148. IUPAC, Compendium of Chemical Terminology, 2nd ed. (the "Gold

Book") 1997. Online corrected version: "biological halflife". 2006

149. Seldin DW. "The development of the clearance concept". J.

Nephrol. 17 (1), 2004, 166.

150. Aldo Rescigno. “Area under the curve and bioavailability”.

Pharmacological Research. Volume 42 (6), 2000, 539.

151. Ennaceur A, Aggleton JP. “The effects of neurotoxic lesions of the

perirhinal cortex combined to fornix transection on object

recognition memory in the rat”. Behav. Brain. Res. 88, 1997, 181.

152. Jayarajan P, Vishwakarma SL, Pendharkar VV, Sharma DC,

Shirsath VS, Ramakrishna NVS. “Effect of selective 5-HT6 receptor

217

antagonists in rodent models of learning”. Society for neuroscience

35th annual meeting, Washington, DC, Nov 12-16, 2005.

218

LIST OF PUBLICATIONS

1. “Novel and Potent 5-Piperazinyl Methyl-N1-aryl Sulfonyl Indole

Derivatives as 5-HT6 Receptor Ligands”

Ramakrishna V. S. Nirogi,*† Prabhakar Kothmirkar,† Ramasastri

Kambhampati,† Jagadish Babu Konda,† Sobhanadri Arepalli,†

Narasimhareddy G. Pamuleti,† Amol D. Deshpande,† Trinathreddy

Bandyala,† Anil K. Shinde,† and P. K. Dubey‡

ACS Med.Chem.Lett. 2010, 1, 340-344.

2. “Convenient and Efficient Synthesis of Some Novel Fused Thieno

Pyrimidines Using Gewald's Reaction”

Ramakrishna V. S. Nirogia, Rama Sastri Kambhampatia,

Prabhakar Kothmirkara, Sobhanadri Arepallia, Narasimha Reddy

G. Pamuletia, Anil K. Shindea & P. K. Dubeyb

Synthetic Communications, 41: 2835-2851, 2011.

3. Synthesis of novel (1-substituted benzenesulfonyl-1H-indol-5-yl)-

(4-substituted piperazin-1-yl)-methanone derivatives as 5-HT6R

ligands

Ramakrishna V. S. Nirogi1, Prabhakar Kothmirkar1,2, Anil K.

Shinde1*, Jagadish Babu K1, K. R. Sastry1 and P. K. Dubey2

Der Pharma Chemica, 2011, 3(3): 221-231.